Herpes Simplex Virus (HSV) Types 1/2 Antibodies, IgM, Immunoblot

Herpes Simplex Virus (HSV) Types 1/2 Antibodies, IgM, Immunoblot is used to evaluate HSV 1/2–associated disease and to corroborate equivocal or weak-positive HSV IgM or IgG enzyme immunoassay findings. The test aids diagnostic assessment in clinical settings where early infection is suspected, including HSV encephalitis, intrauterine fetal infection, and disseminated herpesvirus infection. Synonyms such as HSV 1/2 and herpes simplex virus types 1 and 2 are commonly used for this evaluation.

HSV-1 and HSV-2 are enveloped DNA viruses that establish lifelong latency in sensory ganglia with intermittent reactivation. Transmission occurs through respiratory droplets, direct contact, sexual exposure, and across the placenta. Clinical manifestations span gingivostomatitis, genital herpes, keratoconjunctivitis (more often associated with HSV-1), encephalitis, intrauterine infection, fetal loss, and disseminated neonatal disease (commonly linked to HSV-2). Primary maternal infection in the second or third trimester increases the likelihood of fetal infection. HSV is not considered a teratogen, and clinical outcomes differ from other TORCH pathogens. Immunoblot methodology detects antibodies to discrete HSV antigens with strong analytical performance, provides confirmation of screening enzyme immunoassay results, supports type-specific interpretation based on antigen reactivity patterns (for example, gG-based responses), and assists with infection staging and the recognition of subclinical HSV-1 and HSV-2.